Drug Abuse Clinical Trial
— OPUS ROfficial title:
Etude Observationnelle Prospective de l'Utilisation en Situation Reelle; Prospective Real Situation Observational Study of Subutex® or Its Buprenorphine High Dose Generic (BHD) in the Replacement Treatment of Major Opiate Dependence: Following Parameters With Respect to Misuse and Pharmacovigilance
NCT number | NCT00723697 |
Other study ID # | P05186 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 2007 |
Est. completion date | February 2010 |
Verified date | March 2023 |
Source | Indivior Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to assess the risks of abuse, misuse and adverse events related to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or its Buprenorphine High Dose (BHD) generic (Arrow Laboratories) will participate in this study. Data will be collected using physician questionnaires and self evaluation patient questionnaires at the first visit and visits at 6 and 12 months.
Status | Completed |
Enrollment | 1307 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Eligible patients will be those already having a prescription for Subutex or its BHD generic, or being proposed a prescription for Subutex or its BHD generic for the first time when consulting the participating physician. - The patient must have been informed orally and in writing via the information notice and have signed it. Exclusion Criteria: - Criteria of non-eligibility will be related to the contraindications in the Marketing Authorization (MA) of Subutex or its BHD generic |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Indivior Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients Reporting Misuse (Injection, Sniffing, Dose Fractionation, Modification of Prescribed Doses, and Combination With Psychotropic Agents) | Number of patients who indicate misuse behaviours on self-questionnaire response at first (D1), 6 month (M6), and 12 month (M12) visits. | first visit, 6 months, and 12 months | |
Primary | Number of Patients With Misuse (Injection, Sniffing, Dose Fractionation, Modification of Prescribed Doses, and Combination With Psychotropic Agents) as Reported by Physician. | Number of patients with misuse behaviours on physician-questionnaire response at first (D1), 6 month (M6), and 12 month (M12) visits. | first visit, 6 months, and 12 months | |
Secondary | Number of Patients Reporting Clinical Consequences of Engaging in Misuse | Number of patients with clinical consequences (development or progression of: abscess, nutritional deficiency, dental problems, psychiatric problems including depression, sleep problems, schizophrenia, anxiety, phobias, hallucinations, delirium, withdrawal symptoms, inhibition, suicide attempts and other problems) at first, 6 month, and/or 12 month visit. | first visit, 6 months, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT02375516 -
Preventing Drug Abuse Among Hispanic Adolescents
|
N/A | |
Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
Withdrawn |
NCT01275391 -
cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use
|
Phase 1/Phase 2 | |
Completed |
NCT00907309 -
Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use
|
Phase 1/Phase 2 | |
Completed |
NCT02228044 -
Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment
|
N/A | |
Withdrawn |
NCT01427465 -
Brief Integrative Alcohol Interventions for Adolescents
|
N/A | |
Completed |
NCT00350909 -
Brief Intervention for Drug Abusing Adolescents
|
Phase 2 | |
Completed |
NCT00148031 -
Improving Hepatitis C Treatment in Injection Drug Users
|
Phase 4 | |
Completed |
NCT00383838 -
Self-Selected Brief Alcohol Intervention for Adolescents
|
N/A | |
Completed |
NCT00451854 -
Student Athlete Testing Using Random Notification
|
N/A | |
Completed |
NCT00722644 -
Cognitive Behavioral Stress Management for HIV+ Drug Abusers
|
Phase 1 | |
Completed |
NCT01036711 -
Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
|
||
Terminated |
NCT02741076 -
Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
|
Phase 4 | |
Completed |
NCT01035723 -
Effect of Functional Genetic Polymorphisms on Brain Morphology and Function
|
||
Completed |
NCT06044363 -
Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders
|
N/A | |
Recruiting |
NCT05037487 -
Evaluation of Smoked THC and CBD in Men and Women
|
Phase 1 | |
Recruiting |
NCT04725266 -
A Family-based Intervention for Drug-abusing Adults in Hong Kong
|
N/A | |
Completed |
NCT03678051 -
CBT4CBT for Women in Residential Treatment for Substance Use Disorders
|
N/A |